Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
Fava
Carmen
C
Cortes
Jorge
J
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D002869:Chromosome Aberrations; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics; D002999:Clone Cells / Q000648:ultrastructure; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000209:etiology* / Q000235:genetics; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D014314:Trisomy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate